IN VIVO GENERATION OF ANGIOSTATIN 4.5--CLINICAL TRIAL
IN VIVO GENERATION OF ANGIOSTATIN 4.5--CLINICAL TRIAL
批准号:
6293438
负责人:
TIMOTHY M KUZEL
金额:
$26.84万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-05-01 至 2003-04-30
中文摘要
对于肿瘤的生长和转移,它们必须诱导
新血管的生成,这一过程被称为血管生成。
因此,抑制血管生成提供了重要的新治疗靶点。
血管生成抑制剂angiostatin是一种含有kringle的内源性
纤溶酶原片段,已被证明可以抑制癌症的生长,
许多动物模型。在以前的R01支持的工作在西北
University,Soff等人已经证明了天然的
人血管抑素。纤溶酶原首先被纤溶酶原转化为纤溶酶
激活剂,并且在游离巯基供体的存在下,纤溶酶经历
Kringle 5内的自身蛋白水解产生血管抑素4.5(AS 4.5),其由以下组成:
前4个kringle以及kringle 5的85%。AS4.5存在于
正常和恶性血液和其他标本,是一种有效的抑制剂,
血管生成和体内癌症生长。特别令人感兴趣的是,
在患有癌症的小鼠和人类中进行的实验,
抗血管生成鸡尾酒,由纤溶酶原激活剂和游离的
巯基供体导致AS 4.5水平显著增加,
肿瘤生长虽然正在进行的工作继续在更好地了解性质,
在体外的AS4.5活性,我们有兴趣更严格地研究
在患有晚期恶性肿瘤的人类患者中体内产生AS4.5。的
这一快速试验补助金申请的重点是确定在第一阶段的方式
安全剂量范围内的药物的“鸡尾酒”,即组织纤溶酶原
激活剂(tPA)和美司钠。此外,我们将确定剂量反应
抗血管生成鸡尾酒中的药剂与
AS4.5。这将允许严格计算半衰期,
分布和曲线下面积,这是唯一在体内产生的,
抗肿瘤治疗。
英文摘要
For tumors to grow and metastasize, they must induce the
generation of new blood vessels, a process referred to as angiogenesis.
Inhibition of angiogenesis thus provides an important new therapeutic target.
The angiogenesis inhibitor angiostatin is a kringle-containing internal
fragment of plasminogen, which has been shown to inhibit cancer growth in
numerous animal models. In previous R01-supported work at Northwestern
University, Soff et al. have demonstrated the mechanism of generation of native
human angiostatin. Plasminogen is first converted to plasmin by a plasminogen
activator, and in the presence of a free sulfhydryl donor, plasmin undergoes
autoproteolysis within kringle 5 to yield Angiostatin 4.5(AS4.5), consisting of
the first 4 kringles as well as 85 percent of kringle 5. AS4.5 is present in
normal and malignant blood and other specimens and is a potent inhibitor of
angiogenesis and cancer growth in vivo. Of particular interest, in initial
experiments in mice and humans with cancer, administration of an
antiangiogenesis cocktail, consisting of a plasminogen activator and a free
sulfhydryl donor results in marked increases in AS4.5 levels and inhibition of
tumor growth. While ongoing work continues in better understanding the nature
in vitro of AS4.5 activity, we are interested in more rigorously studying the
in vivo generation of AS4.5 in human patients with advanced malignancies. The
focus of this quick trial grant application is to determine in Phase I fashion
the safe dosage range of drugs in the "cocktail," namely tissue plasminogen
activator (tPA) and mesna. In addition, we will determine the dose response
relationship of the agents in the antiangiogenesis cocktail with the levels of
AS4.5. This will allow a rigorous calculation of the half-life, volume of
distribution and area under the curve of this uniquely in vivo-generated
anti-neoplastic therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
clinical research office
-
批准号:8486519
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2012
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:7339477
-
项目类别:
-
资助金额:$41.91万
-
财政年份:2007
-
负责人:TIMOTHY M KUZEL
-
依托单位:
IN VIVO GENERATION OF ANGIOSTATIN 4.5--CLINICAL TRIAL
-
批准号:6514900
-
项目类别:
-
资助金额:$26.84万
-
财政年份:2001
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:8309432
-
项目类别:
-
资助金额:$45.44万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:7920986
-
项目类别:
-
资助金额:$48.77万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:8135589
-
项目类别:
-
资助金额:$47.68万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
PREVENT 5-FLUORACIL INDUCED COAGULATION ACTIVATION W/SUBCUTANEOUS HEPARIN
-
批准号:3893006
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位:
clinical research office
-
批准号:7666678
-
项目类别:
-
资助金额:$48.47万
-
财政年份:--
-
负责人:TIMOTHY M KUZEL
-
依托单位: